Seres Therapeutics Reports Positive SER-155 Clinical Data for irEC, Bolstering Partnership Efforts
MCRB sits 64% above its 52-week low of $5.31.
Summary
Seres Therapeutics announced encouraging top-line results from an investigator-sponsored trial of SER-155 for immune checkpoint inhibitor-related enterocolitis (irEC), demonstrating high rates of immunosuppressive-free clinical response and supporting further development and potential partnerships.
Key Events · Product Development and Regulatory · MCRB
-
Positive SER-155 irEC Trial Results
In an investigator-sponsored trial of SER-155 for immune checkpoint inhibitor-related enterocolitis (irEC) involving 15 patients, 80% achieved an immunosuppressive-free clinical response at Day 15, the primary endpoint. Additionally, 33% achieved complete clinical remission.
-
Strong Safety Profile
SER-155 was generally well-tolerated through Day 43, with no safety concerns identified, no serious adverse events assessed as related to the drug, and no bloodstream infections reported.
-
Mechanism of Action Confirmed
Pharmacology data showed robust SER-155 bacterial strain engraftment and statistically significant reductions in biomarkers of gastrointestinal inflammation and mucosal epithelial barrier damage by Day 43.
-
Strategic Partnership Focus
The company is actively engaging with potential partners, including those with ICI franchises, to evaluate next steps for SER-155 development in irEC, and continues to seek funding for its Phase 2 allo-HCT study and broader pipeline.
Analysis · MCRB · Life Sciences
The positive top-line results for SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC) are a critical development for Seres Therapeutics, a company operating under a 'going concern' warning and actively seeking funding. These encouraging clinical and pharmacological data provide strong validation for SER-155's potential, making it significantly more attractive for strategic partnerships. Securing such partnerships is vital for the company to obtain the necessary capital to advance SER-155 and its broader pipeline, which is essential for extending its cash runway beyond Q1 2027 and addressing its urgent financial needs.
At the time of this filing, MCRB was trading at $8.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.8M. The 52-week trading range was $5.31 to $29.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.